PORTEFEUILLE

Présentation des projets sur le site web

Chaque projet soutenu par Gebert Rüf Stiftung est présenté sur le site web de la fondation avec en particulier les données de base du projet. Par cette publication, la fondation informe sur les résultats du soutien accordé et contribue à la communication scientifique au sein de la société.

Close

SenSonic

Rédaction

Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.

Coopération

Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen: heig-vd, Institute of Information and Communication Technologies; Oslo University Hospital, Norway; Medtronic Bakkens research center, Netherlands; Imasonic, Besançon, France

Données de projet

  • Numéro du projet: GRS-055/12 
  • Subside accordé: CHF 95'000 
  • Consentement: 24.01.2013 
  • Durée: 08.2013 - 06.2016 
  • Champs d'activité:  Pilotprojekte, 1998 - 2018

Direction du projet

Description du projet

The present state of the art of implanted devices is based on primary batteries, i.e. which cannot be recharged when depleted, i.e. the patient must be operated to change the device. Slowly, new implanted devices are appearing which can be recharged with radio-frequency waves, with antennas or coils which needed to be placed close to the skin because the radio waves are strongly absorbed by the body tissues.

The present project uses ultrasound, which propagates deeply into the body, to communicate with the implant and to recharge its battery. This opens the way to a new breed of implanted monitoring devices which can be “implanted and forgotten” and brought to life when needed, by recharging them through an external device applied to the skin. Another goal of this project is to provide a demonstrator for these innovative uses of ultrasound. The Oslo University Hopital is also interested to use them for in-vivo testing.

Quelles sont les particularités de ce projet?

The innovation is in the use of ultrasound for in-body communication and energy transfer, as opposed to diagnostic and treatment. The particularity of this project is to use asymmetric communication, where all the burden of the power and complexity is on the external device applied to the skin, leaving a very simple and very low power implanted device.

Beyond the medical field, as ultrasounds propagate well through homogeneous solids and liquids, this technology can be applied in the fields of oil industry (communication through pipes) or chemical, food and biotech industry (monitoring of reactors and processing tanks).

Etat/résultats intermédiaires

The electronics has been redesigned into a new demonstrator, packaged in a titanium casing. This demonstrator now uses commercially available components, offering an evolution path to an implantable solution.

Piezoelectric transducers are highly non-standard products, which are only custom-designed and built by their manufacturer. Unfortunately, we had shortcomings with the partner that was intended to supply the piezo transducers, who chose not to deliver new devices, for reasons of their own. Thus we could not test thoroughly the demonstrator in the testing tank, as was intended first. Of course, that made it also impossible to perform the animal tests.

The Wyss Center for Bio and Neuro Engineering in Geneva (http://www.wysscenter.ch) has expressed interest in the technology, and the project is foreseen to continue, offering further possibilities of development of this very interesting technology.

Publications

Publication foreseen in Jan 2014 in HES-SO/HEIG-VD newsletter.

Liens

Personnes participant au projet

Dominique Bovey, University of Applied Sciences of Western Switzerland, project manager dominique.notexisting@nodomain.combovey@heig-vd.notexisting@nodomain.comch
Pascal Coeudevez, University of Applied Sciences of Western Switzerland pascal.notexisting@nodomain.comcoeudevez@heig-vd.notexisting@nodomain.comch
Dr Ing Ilankgo Balasinghan, researcher, Oslo University Hospital ilangko.notexisting@nodomain.combalasinghan@medisin.notexisting@nodomain.comuio.notexisting@nodomain.comno
Dr Jacob Bergsland, cardiologist, Oslo University Hospital jbergsland@ous-hf.notexisting@nodomain.comno

Dernière mise à jour de cette présentation du projet  17.10.2018